InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

62.7/100

Rank #687 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

LIVN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for LivaNova PLC (LIVN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LIVN at 62.7/100 on a 32-signal composite quality model, placing it at rank #687 of 2,961 stocks — the top 25% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), LivaNova PLC reports quarterly revenue of $390.6M, net income of $108.6M, an operating margin of 12.7%. Top institutional holders of LIVN by reported 13-F value include BlackRock, PRIMECAP MANAGEMENT, FMR, based on the most recent SEC filings. LIVN trades on the Nasdaq exchange and files with the SEC under CIK 1639691. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LIVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LivaNova PLC directly from SEC EDGAR. LivaNova PLC's 13F Pro composite quality score has ranged between 46 and 63 since 2026, currently 62.7 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.

Fun facts about LivaNova PLC

Quirks, history, and lore behind LIVN — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A UK-headquartered medical device company · listed on Nasdaq · operating across neuromodulation and cardiac surgery · with a global commercial footprint.
  • 2
    The Numbers
    Annual revenue in the range of roughly $1 billion — small-cap territory — yet it serves patients in over 100 countries with life-altering implantable devices.
  • 3
    The History
    The company was formed in 2015 when two legacy medical-device businesses — one Italian, one American — merged to create a single neuro and cardiac specialist.
  • 4
    The Secret
    Its vagus nerve stimulation therapy is FDA-approved for both epilepsy and treatment-resistant depression — a device that literally rewires your mood.
  • 5
    The Lore
    One of its founding lineages traces back to Sorin Group, an Italian spinoff of chemical giant Fiat-Solvay, making it a rare medical company with roots in the auto industry.
  • 6
    The Giveaway
    It makes the VNS Therapy System — a pacemaker-like implant for your brain — and its ticker rhymes with the Latin word for life.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$390.6M

Net Income

Q2 2026

$108.6M

Free Cash Flow

Q2 2026

$35.0M

Operating Margin

Q2 2026

12.7%

ROIC

Q2 2026

12.2%

D/E Ratio

Q2 2026

0.22

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+10.7% YoY
$1.39BFY 2025
FY22 $1.02BFY23 $1.15BFY24 $1.25BFY25 $1.39B

Net Income

-483.5% YoY
$-242.5MFY 2025
FY22 $-86.2MFY23 $17.5MFY24 $63.2MFY25 $-242.5M

Operating Income

+54.5% YoY
$199.4MFY 2025
FY22 $-76.8MFY23 $-68.5MFY24 $129.1MFY25 $199.4M

EPS (Diluted)

-483.6% YoY
$-4.45FY 2025
FY22 $-1.61FY23 $0.32FY24 $1.16FY25 $-4.45

Total Assets

+4.0% YoY
$2.61BFY 2025
FY22 $2.29BFY23 $2.43BFY24 $2.51BFY25 $2.61B

Total Debt

-44.0% YoY
$438.4MFY 2025
FY22 $583.3MFY23 $621.6MFY24 $782.3MFY25 $438.4M

Op. Cash Flow

+39.0% YoY
$254.3MFY 2025
FY22 $69.9MFY23 $74.9MFY24 $183.0MFY25 $254.3M

Free Cash Flow

+27.5% YoY
$173.3MFY 2025
FY22 $43.4MFY23 $39.9MFY24 $135.9MFY25 $173.3M

Get alerted when LIVN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LivaNova PLC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of LIVN

Companies Similar to LIVN

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

INSP

Inspire Medical Systems, Inc.

60
AI score
Similar quality profile · 15 shared holders
VCYT

VERACYTE, INC.

67
AI score
Similar quality profile · 17 shared holders
TMDX

TransMedics Group, Inc.

67
AI score
Similar quality profile · 17 shared holders
ANIP

ANI PHARMACEUTICALS INC

68
AI score
Similar quality profile · 28 shared holders
LMAT

LEMAITRE VASCULAR INC

67
AI score
Similar quality profile · 17 shared holders
INVA

Innoviva, Inc.

68
AI score
Similar quality profile · 17 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put LIVN on your watchlist

Track score changes the day LivaNova PLC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is LIVN a good stock to buy?

13F Pro's AI-powered analysis of LivaNova PLC (LIVN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LIVN are available on the LIVN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LIVN is classified as a mid company.

Which hedge funds own LIVN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LIVN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LivaNova PLC's investment landscape.